Emerging Role of Renal Sympathetic Denervation as an Adjunct Therapy to Atrial Fibrillation Ablation

Krittapoom Akrawinthawong1, Takumi Yamada2

  • 1Section of Cardiac Electrophysiology, University of Oklahoma Health Science Center, Oklahoma City, OK 73104, USA.

Insights

Pulmonary vein isolation (PVI) for atrial fibrillation (AF) has limitations. Renal denervation (RDN) is emerging as a complementary strategy to improve long-term AF rhythm control and patient outcomes.

Area of Science:

  • Cardiology
  • Electrophysiology
  • Interventional Cardiology

Background:

  • Pulmonary veins are the primary target for atrial fibrillation (AF) ablation.
  • Pulmonary vein isolation (PVI) offers modest long-term success, driving research into alternative strategies.
  • Previous alternative targets have not matched PVI's routine use.

Purpose of the Study:

  • To review current AF ablation strategies.
  • To explore the role of the autonomic system in AF pathophysiology.
  • To evaluate renal denervation (RDN) as a complementary therapy to PVI for AF rhythm control.

Main Methods:

  • Literature review of AF ablation techniques.
  • Analysis of the autonomic system's role in AF.
  • Assessment of RDN as an adjunct to PVI.

Main Results:

  • No alternative ablation targets have become routine beyond PVI.
  • The autonomic system presents a potential target for AF management.
  • RDN shows promise as an adjunct to PVI.

Conclusions:

  • Further refinement of ablation strategies is crucial for improving AF patient outcomes.
  • RDN is an emerging technique that may enhance long-term success in AF rhythm-control strategies.
  • Combining RDN with PVI could significantly improve therapeutic efficacy for AF.

Related Concept Videos

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
413
Antihypertensive Drugs: Direct Renin Inhibitors01:25

Antihypertensive Drugs: Direct Renin Inhibitors

The renin-angiotensin-aldosterone system (RAAS) is an intricate physiological pathway involving numerous enzymes and hormones, including renin, angiotensin-converting enzyme (ACE), angiotensin I and II, and aldosterone. Imbalances within this system increase the production of angiotensin II and aldosterone. Increased angiotensin II levels promote vasoconstriction and blood pressure elevation. Concurrently, higher aldosterone levels stimulate sodium and water reabsorption in the kidneys,...
521
Heart Failure Drugs: Diuretics01:22

Heart Failure Drugs: Diuretics

Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
355
Antihypertensive Drugs: Angiotensin II Receptor Blockers01:30

Antihypertensive Drugs: Angiotensin II Receptor Blockers

In the renin-angiotensin-aldosterone system, a hormone called angiotensin II plays a crucial role. It binds to the AT1 receptors in vascular smooth muscles coupled with Gq proteins. The activation of these receptors activates an enzyme called phospholipase C, which releases two molecules: inositol trisphosphate and diacylglycerol. These molecules cause a chain reaction that leads to the phosphorylation of myosin light chains and promotes interaction between actin and myosin, leading to smooth...
674
Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors01:30

Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors

Angiotensin-converting enzyme (ACE), a vital component of the renin-angiotensin-aldosterone system, is abundant in lung endothelial cells. ACE converts the inactive decapeptide, angiotensin I, into the active octapeptide, angiotensin II. This potent vasoconstrictor narrows blood vessels, increasing resistance to blood flow and elevating blood pressure. Angiotensin II also stimulates aldosterone production, encouraging kidney cells to reabsorb more sodium and water from urine, thereby increasing...
578